NCT06116565

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

An Multi-center, Open-label, Single-arm Phase 2 Study to Evaluate the Long-term Safety and Efficacy of CM310 in Subjects With Moderate-to-severe Atopic Dermatitis

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.

Detailed description

The study consists of an screening period, treatment period, and safety follow-up period.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
BIOLOGICAL	CM310	CM310, subcutaneous injection

Timeline

• Start date: 2024-03-30
• Primary completion: 2026-03-30
• Completion: 2026-03-30
• First posted: 2023-11-03
• Last updated: 2023-11-03